References
- Petterson F. editor. Annual report on the results of treatment in gynecological cancer, Radiumhemmet, Stockholm, Sweden. Int J Gynecol Obstet 1990; 243
- Averette H E, Hoskins W, Nquyen H N, et al. National survey of ovarian carcinoma. Cancer 1993; 71(Suppl.)1629–39
- Colombo N, Pitelli M R, Parma G, et al. Cisplatin dose intensity in advanced ovarian cancer (AOC). A randomized study of conventional dose (DC) vs dose‐intense (DI) cisplatin chemotherapy. Proc. ASCO 1993; 12(806)255
- Hainsworth D J, Grosh W W, Burnett L S, Jones H, Wolff S, Creco A. Advanced ovarian cancer: Long‐term results with intensive cisplatin‐based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165–9
- Dershaw D, Panicek D M. Radiologic evaluation of ovarian cancer. Cancer of the ovary, M Markman, W J Hoskins. Raven Press, Ltd, New York 1993; 133–52
- Welander C. What do CA‐125 and other antigens tell us about ovarian cancer biology?. Acta Obstet Gynecol Scand 1992; 71(Suppl. 155)85–93
- Goldhirsch A, Triller J K, Greenner R. Computed tomography prior to second‐look operation in advanced ovarian cancer. Obstet Gynaecol 1983; 62: 630
- SAS Institute Inc. SAS/STAT Guide for Personal Computers 19876 edition. Cary, NCUSA 1987
- Rubin S, Hoskins W J, Hakes T, et al. Serum CA‐125 levels and surgical findings in patients undergoing second‐look operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989; 160: 667–71
- Hoskins W J, Rubin S C. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213–21
- Haq R, Sturgean J R G, Rosen B, et al. Comparison of CA‐125 and CT scan with second‐look laparotomy in assessing response of advanced ovarian cancer to chemotherapy (Abstract 299). Second Meeting, International Gynecologic Cancer Society, Toronto, 1989